Eli Lilly (LLY)

Eli Lilly stock has already rallied 70% in less than four months.

Eli Lilly stock inches higher as the company joins the coveted trillion-dollar club. Citi analysts believe LLY shares will push meaningfully higher in 2026.

Eli Lilly hit a $1 trillion valuation for the first time, becoming the only healthcare company to reach the milestone as demand for its weight-loss drugs continues to surge.

Eli Lilly and Co (NYSE:LLY) shares are trading higher on Friday. The company plans to start selling its obesity drug through a new approach aimed at expanding access.

The company’s GLP-1 drugs, Zepbound and Mounjaro, have driven investor appetite and pushed its share price by about 40% this year.

Concerns are mounting across financial markets regarding a potential "AI bubble," as sky-high valuations for technology companies, particularly those focused on artificial intelligence, trigger comparisons to past speculative frenzies. This apprehension is influencing market sentiment, leading to significant volatility and a re-evaluation of investment strategies. While the transformative power of AI is undeniable, the sustainability [...]

Eli Lilly became the first health care company to top $1 trillion in market capitalization on Friday.

Eli Lilly (LLY) just became the first healthcare company to join the $1 trillion market cap club. Shares are trading at a new all-time high on Friday, Nov. 21. The stock is up 40% in the past year and nearly 80% in the past two years. Analysts remain...

The management team conducted a cost-cutting effort that is likely to result in a more efficient business.

KeyCorp, through its KeyBanc capital markets division, has issued a significantly more pessimistic forecast for LifeMD (NASDAQ: LFMD) stock, dramatically lowering its price objective to $8.00 from a previous $12.00. This downgrade reflects growing concerns over the telehealth company's financial performance, operational efficiency, and competitive landscape. The immediate

Novo Nordisk just addressed a problem that has prevented some from taking these drugs.

Indianapolis, IN – November 19, 2025 – Eli Lilly and Company (NYSE: LLY), the pharmaceutical titan, finds itself at the epicenter of market speculation, firmly placed on "stock split watch" as its share price has soared past the formidable $1,000 mark. This extraordinary ascent, fueled by groundbreaking drug innovations and robust

Eli Lilly (LLY) stands out for its diversified pharmaceutical portfolio, robust pipeline, and strategic acquisitions that are fueling growth. LLY has strong technical momentum and is trading at new all-time highs. Shares are up 43% over the past year...

Don't wait for a stock split to buy the stock, though.

These stocks both have advanced in the double-digits in recent months.

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish line.